NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

CompletedN/A

Sponsor: AstraZeneca

Conditions: Carcinoma, Non-Small-Cell Lung

Countries: Japan

To collect information of safety in patients with unresectable advanced or recurrent non-small cell lung cancer who receive combination therapy of IMJUDO, IMFINZI and other platinum-based anti-cancer agents under actual use in the postmarketing setting.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* All patients who receive IMJUDO, IMFINZI and other platinum-based anti-cancer agents for their unresectable advanced or recurrent NSCLC

Exclusion Criteria:

\-

Locations (28)

Aichi, Japan
Chiba, Japan
Fukuoka, Japan
Fukushima, Japan
Gifu, Japan
Gunma, Japan
Hiroshima, Japan
Hokkaido, Japan
Hyōgo, Japan
Ibaraki, Japan
Ishikawa, Japan
Kagawa, Japan
Kanagawa, Japan
Kyoto, Japan
Mie, Japan
Miyagi, Japan
Miyazaki, Japan
Nara, Japan
Okayama, Japan
Osaka, Japan
Shizuoka, Japan
Tochigi, Japan
Tokyo, Japan
Tottori, Japan
Toyama, Japan
Wakayama, Japan
Yamagata, Japan
Yamaguchi, Japan